A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve outcomes for patients. Here are some key details about the study:
- The study is unique because it combines multiple treatment methods, which may enhance effectiveness compared to standard therapies.
- It involves a specific group of patients who have not responded well to previous treatments, making it particularly relevant for those seeking new options.
- Researchers are looking at how well these combined therapies work together and their potential to reduce symptoms and improve quality of life.
- The study also aims to understand the safety of these treatments and any side effects that may occur.
- Patients will be monitored closely throughout the study to gather important data on their health and response to the treatment.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
